Dexcom's market growth accelerates with clinical wins and new paediatric approval amid intensifying competition

Dexcom’s latest quarter highlights a 13% revenue rise driven by clinical advances and FDA clearance for paediatric use, as the company aims to outpace rivals in a crowded CGM market, despite operational challenges. Dexcom’s latest quarter gave investors several reasons…













